View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
January 8, 2021updated 11 Jul 2022 9:52am

AM-Pharma enrols first Covid-19 patients in Phase III clinical trial

AM-Pharma has announced the enrolment of first participants in an exploratory cohort in Phase III REVIVAL pivotal trial of its human recombinant alkaline phosphatase (AP) for treating patients with Covid-19 and sepsis-associated acute kidney injury (SA-AKI).

AM-Pharma has announced the enrolment of first participants in an exploratory cohort in Phase III REVIVAL pivotal trial of its human recombinant alkaline phosphatase (AP) for treating patients with Covid-19 and sepsis-associated acute kidney injury (SA-AKI).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The therapeutic candidate derives from two naturally occurring human isoforms of the AP enzyme.

For the Covid-19 cohort clinical study, Dutch Ministry of Economic Affairs and Climate Policy-established Netherlands Enterprise Agency (RVO) extended an innovation credit of up to €5m to AM-Pharma.

The randomised, double-blind, placebo-controlled, two-arm, parallel-group, multi-centre trial will analyse the efficacy and safety of the compound for treating patients with SA-AKI.

The main study population will include around 1400 patients with SA-AKI. Up to 100 patients with moderate chronic kidney disease (CKD) and up to 100 patients with Covid-19 will be enrolled in two exploratory groups.

Proving the improvement in the primary endpoint of 28-day all-cause mortality, as seen in the Phase II STOP-AKI study, will form the study’s primary endpoint.

Effect of the therapy on long-term Major Adverse Kidney Events (MAKE), on the use of organ support, ICU stay length and on 90-day all-cause mortality are some of the secondary endpoints.

AM-Pharma noted that severe Covid-19 patients often have acute severe inflammation and organ failure.

According to latest studies carried out in the US, up to 90% of the Covid-19 patients who received mechanical ventilation also had AKI and its development is linked to poor prognosis.

AM-Pharma CEO Erik van den Berg said: “The prevalence of Covid-19 infections and the high AKI comorbidity support our decision to include this additional cohort into our Phase III REVIVAL pivotal study.

“By providing our proprietary recombinant alkaline phosphatase to clinicians for evaluation in severe Covid-19 cases, we aim to make our novel treatment option available for these patients.”

In July 2019, AM-Pharma raised €116m from a European syndicate of new and existing investors to support the initiation of a Phase III trial of its recombinant human alkaline phosphatase (recAP) therapeutic for patients with SA-AKI.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology